ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

BHVN Biohaven Ltd

40.69
0.79 (1.98%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Biohaven Ltd BHVN NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.79 1.98% 40.69 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
40.72 40.45 42.105 40.69 39.90
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202415:05PRNUSBiohaven Announces Closing of Public Offering and Full..
17/4/202415:05PRNUSBiohaven Announces Proposed Public Offering of Common Shares
13/4/202408:00PRNUSBiohaven Showcases Innovative Neuroscience Portfolio with 20..
29/2/202415:16EDGAR2Form 8-K - Current report
29/2/202415:05PRNUSBiohaven Reports Fourth Quarter and Full Year 2023 Financial..
08/1/202406:30EDGAR2Form 8-K - Current report
08/1/202406:30PRNUSBiohaven Highlights Progress Across Innovative Portfolio and..
02/1/202406:00PRNUSBiohaven to Present at the 42nd Annual J.P. Morgan..
01/12/202315:30PRNUSBiohaven Presents Expanded EEG and Safety Data for BHV-7000..
14/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202315:05PRNUSBiohaven Reports Third Quarter 2023 Financial Results and..
16/10/202306:00PRNUSBiohaven Presents Preclinical Data Demonstrating..
05/10/202315:05EDGAR2Form 8-K - Current report
05/10/202315:05PRNUSBiohaven Announces Closing of Public Offering and Full..
04/10/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202322:56PRNUSBiohaven Announces Pricing of $225 Million Public Offering..
02/10/202320:41EDGAR2Form 8-K - Current report
02/10/202316:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202316:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202315:36PRNUSBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
02/10/202315:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27/9/202305:58EDGAR2Form 8-K - Current report
14/9/202306:00PRNUSBiohaven Completes Enrollment in Pivotal Phase 3 Study of..
05/9/202306:00PRNUSBiohaven Announces Positive Data from its Exploratory..
31/7/202316:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202315:29EDGAR2Form 8-K - Current report
31/7/202308:31PRNUSBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug..
31/7/202305:59PRNUSBiohaven Reports Second Quarter 2023 Financial Results and..
28/7/202315:35EDGAR2Form 8-K - Current report
27/7/202307:42DJNBiohaven Told That FDA Won't Review NDA Application for..
27/7/202306:00PRNUSBiohaven Provides Preliminary EEG Data Update for Kv7..
31/5/202306:00PRNUSBiohaven Provides Overview of Clinical Progress, Regulatory..
25/5/202316:00PRNUSBiohaven to Present R&D Day at Yale School of Management
12/5/202315:30PRNUSBiohaven Reports First Quarter 2023 Financial Results and..

Su Consulta Reciente

Delayed Upgrade Clock